Methods for detecting and treating endometriosis
Provided is a method of non-invasively diagnosing endometriosis in a subject comprising maintaining or culturing stromal cells, obtained from a menstrual effluent or discharge sample from the subject. Also provided is a method of non-invasively diagnosing fertility in a subject. Also provided is a kit for non-invasively diagnosing endometriosis in a subject. Also provided is a method of treating endometriosis in a subject. Also provided is a method of preventing the progression or development of endometriosis in a subject.
1. A method of treating endometriosis in a subject comprising:
a) obtaining an identification of the subject as in need of treatment of endometriosis, wherein the subject has been identified as having endometriosis by:
(i) maintaining a stromal fibroblast cell (SFC), obtained from a menstrual discharge sample from the subject, under conditions permitting decidualization, quantifying a rate or extent of decidualization of the stromal fibroblast cell, and comparing the rate of decidualization to a control value of decidualization indicative of a subject without endometriosis, wherein a rate or extent of decidualization of the stromal fibroblast cell which is less than that of the control value of decidualization indicates that the subject has endometriosis; or
(ii) quantitating expression of ALDH1A1 protein in a stromal fibroblast cell obtained from a menstrual discharge sample from the subject and comparing the expression quantitated to a control value of expression of the ALDH1A1 protein indicative of a subject without endometriosis, wherein an amount of expression quantitated less than the control value indicates that the subject has endometriosis;
and
b) treating the subject so-identified as having endometriosis by performing a laproscopic surgery or hysterectomy, or administering an amount of a progestin, a gonadotropin-releasing hormone agonist or a birth control pill effective to treat endometriosis.
2. The method of claim 1 , wherein the subject has been identified as having endometriosis by maintaining a stromal fibroblast cell, obtained from a menstrual discharge sample from the subject, under conditions permitting decidualization, quantifying a rate or extent of decidualization of the stromal fibroblast cell, and comparing the rate of decidualization to a control value of decidualization indicative of a subject without endometriosis, wherein a rate or extent of decidualization of the stromal fibroblast cell which is less than that of the control value of decidualization indicates that the subject has endometriosis.
3. The method of claim 2 , wherein the menstrual discharge sample comprises menstrual blood.
4. The method of claim 2 , further comprising obtaining the menstrual discharge sample from the subject.
5. The method of claim 2 , wherein the stromal fibroblast cell is contacted with 8-Br-CAMP and one or more hormones to effect decidualization.
6. The method of claim 5 , wherein the one or more hormones comprise 17-beta estradiol and medroxyprogesterone.
7. The method of claim 2 , wherein the rate or extent of decidualization is quantified by measuring IGFBP-1 production by the stromal fibroblast cell.
8. The method of claim 2 , wherein the SFC is identified so as being: CD45−/CD326−/CD31−/CD90+/CD105+/CD73+.
9. The method of claim 8 , wherein the SFC is also CD140b+.
10. The method of claim 1 , wherein the subject has been identified as having endometriosis by quantitating expression of ALDH1A1 proteins in a stromal fibroblast cell obtained from a menstrual discharge sample from the subject and comparing the expression quantitated to a control value of expression of the ALDH1A1 indicative of a subject without endometriosis, wherein an amount of expression quantitated less than the control value indicates that the subject has endometriosis.
11. The method of claim 10 , wherein quantitating the ALDH1A1 proteins comprises measuring protein-encoding RNA levels.